Selected research
Industry Growth & Trends
Global Neurodegenerative Disease IVD Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Neurodegenerative Disease IVD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Neurodegenerative Disease IVD market include ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity and Roche Diagnostics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Neurodegenerative Disease IVD market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Neurodegenerative Disease IVD market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurodegenerative Disease IVD market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurodegenerative Disease IVD.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Neurodegenerative Disease IVD market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Neurodegenerative Disease IVD Market by Company
ADx Neurosciences
Analytik Jena
Beckman Coulter
Creative Biolabs
Fujirebio
Genemedi
Medix Biochemica
Revvity
Roche Diagnostics
Neurodegenerative Disease IVD Segment by Type
Protein Biomarker Detection
Nucleic Acid Biomarker Detection
Others
Neurodegenerative Disease IVD Segment by Application
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others
Neurodegenerative Disease IVD Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease IVD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease IVD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease IVD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Neurodegenerative Disease IVD companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Protein Biomarker Detection
- Nucleic Acid Biomarker Detection
- Others
Applications
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Others
Companies covered
- ADx Neurosciences
- Analytik Jena
- Beckman Coulter
- Creative Biolabs
- Fujirebio
- Genemedi
- Medix Biochemica
- Revvity
- Roche Diagnostics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Neurodegenerative Disease IVD Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Neurodegenerative Disease IVD Market Size by Region (2021-2032)
- 1.4.1 Global Neurodegenerative Disease IVD Market Size by Region (2021-2026)
- 1.4.2 Global Neurodegenerative Disease IVD Market Size by Region (2027-2032)
- 1.5 Key Regions Neurodegenerative Disease IVD Market Size (2021-2032)
- 1.5.1 North America Neurodegenerative Disease IVD Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Neurodegenerative Disease IVD Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Neurodegenerative Disease IVD Market Size Growth Rate (2021-2032)
- 1.5.4 South America Neurodegenerative Disease IVD Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Neurodegenerative Disease IVD Market Size Growth Rate (2021-2032)
2 Neurodegenerative Disease IVD Market by Type
- 2.1 Type Introduction
- 2.1.1 Protein Biomarker Detection
- 2.1.2 Nucleic Acid Biomarker Detection
- 2.1.3 Others
- 2.2 Global Neurodegenerative Disease IVD Market Size by Type
- 2.2.1 Global Neurodegenerative Disease IVD Market Size Overview by Type (2021-2032)
- 2.2.2 Global Neurodegenerative Disease IVD Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Neurodegenerative Disease IVD Market Size Forecasted by Type (2027-2032)
- 2.3 Global Neurodegenerative Disease IVD Market Size by Regions
- 2.3.1 North America Neurodegenerative Disease IVD Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Neurodegenerative Disease IVD Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Neurodegenerative Disease IVD Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Neurodegenerative Disease IVD Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Neurodegenerative Disease IVD Market Size Breakdown by Type (2021-2026)
3 Neurodegenerative Disease IVD Market by Application
- 3.1 Type Introduction
- 3.1.1 Alzheimer's Disease
- 3.1.2 Parkinson's Disease
- 3.1.3 Huntington's Disease
- 3.1.4 Amyotrophic Lateral Sclerosis (ALS)
- 3.1.5 Multiple System Atrophy (MSA)
- 3.1.6 Progressive Supranuclear Palsy (PSP)
- 3.1.7 Others
- 3.2 Global Neurodegenerative Disease IVD Market Size by Application
- 3.2.1 Global Neurodegenerative Disease IVD Market Size Overview by Application (2021-2032)
- 3.2.2 Global Neurodegenerative Disease IVD Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Neurodegenerative Disease IVD Market Size Forecasted by Application (2027-2032)
- 3.3 Global Neurodegenerative Disease IVD Market Size by Regions
- 3.3.1 North America Neurodegenerative Disease IVD Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Neurodegenerative Disease IVD Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Neurodegenerative Disease IVD Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Neurodegenerative Disease IVD Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Neurodegenerative Disease IVD Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Neurodegenerative Disease IVD Industry Trends
- 4.2 Neurodegenerative Disease IVD Industry Drivers
- 4.3 Neurodegenerative Disease IVD Industry Opportunities and Challenges
- 4.4 Neurodegenerative Disease IVD Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Neurodegenerative Disease IVD Revenue (2021-2026)
- 5.2 Global Neurodegenerative Disease IVD Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Neurodegenerative Disease IVD Key Company Headquarters & Area Served
- 5.4 Global Neurodegenerative Disease IVD Company, Product Type & Application
- 5.5 Global Neurodegenerative Disease IVD Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Neurodegenerative Disease IVD Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Neurodegenerative Disease IVD Players Market Share by Revenue in 2025
- 5.6.3 2025 Neurodegenerative Disease IVD Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 ADx Neurosciences
- 6.1.1 ADx Neurosciences Company Information
- 6.1.2 ADx Neurosciences Business Overview
- 6.1.3 ADx Neurosciences Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio
- 6.1.5 ADx Neurosciences Recent Developments
- 6.2 Analytik Jena
- 6.2.1 Analytik Jena Company Information
- 6.2.2 Analytik Jena Business Overview
- 6.2.3 Analytik Jena Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Analytik Jena Neurodegenerative Disease IVD Product Portfolio
- 6.2.5 Analytik Jena Recent Developments
- 6.3 Beckman Coulter
- 6.3.1 Beckman Coulter Company Information
- 6.3.2 Beckman Coulter Business Overview
- 6.3.3 Beckman Coulter Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Beckman Coulter Neurodegenerative Disease IVD Product Portfolio
- 6.3.5 Beckman Coulter Recent Developments
- 6.4 Creative Biolabs
- 6.4.1 Creative Biolabs Company Information
- 6.4.2 Creative Biolabs Business Overview
- 6.4.3 Creative Biolabs Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Creative Biolabs Neurodegenerative Disease IVD Product Portfolio
- 6.4.5 Creative Biolabs Recent Developments
- 6.5 Fujirebio
- 6.5.1 Fujirebio Company Information
- 6.5.2 Fujirebio Business Overview
- 6.5.3 Fujirebio Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Fujirebio Neurodegenerative Disease IVD Product Portfolio
- 6.5.5 Fujirebio Recent Developments
- 6.6 Genemedi
- 6.6.1 Genemedi Company Information
- 6.6.2 Genemedi Business Overview
- 6.6.3 Genemedi Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Genemedi Neurodegenerative Disease IVD Product Portfolio
- 6.6.5 Genemedi Recent Developments
- 6.7 Medix Biochemica
- 6.7.1 Medix Biochemica Company Information
- 6.7.2 Medix Biochemica Business Overview
- 6.7.3 Medix Biochemica Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Medix Biochemica Neurodegenerative Disease IVD Product Portfolio
- 6.7.5 Medix Biochemica Recent Developments
- 6.8 Revvity
- 6.8.1 Revvity Company Information
- 6.8.2 Revvity Business Overview
- 6.8.3 Revvity Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Revvity Neurodegenerative Disease IVD Product Portfolio
- 6.8.5 Revvity Recent Developments
- 6.9 Roche Diagnostics
- 6.9.1 Roche Diagnostics Company Information
- 6.9.2 Roche Diagnostics Business Overview
- 6.9.3 Roche Diagnostics Neurodegenerative Disease IVD Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio
- 6.9.5 Roche Diagnostics Recent Developments
7 North America
- 7.1 North America Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 7.3 North America Neurodegenerative Disease IVD Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 8.3 Europe Neurodegenerative Disease IVD Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Neurodegenerative Disease IVD Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 10.3 South America Neurodegenerative Disease IVD Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Neurodegenerative Disease IVD Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst